FIVE URINARY BIOMARKERS: EARLY DETECTION AND MANAGEMENT OF ACUTE KIDNEY INJURY IN SEPTIC PATIENTS

Authors

  • Dr Maham Javed Malik
  • Dr Rawda Ahmed Mehanna
  • Dr Fiza Majeed
  • Dr Afeera Muqeem Khan
  • Dr Rawan Ahmed Mehanna
  • Dr Uswa Tahir
  • Dr Siddiqua Shahul Hameed
  • Dr Dhoha Mohamed Ahmed Alsalmi
  • Dr Ashtar Kariem
  • Dr Aya Albalooshi

DOI:

https://doi.org/10.53555/yaqqjd18

Keywords:

.

Abstract

Background: Acute kidney injury (AKI) is a complex clinical syndrome characterized by a sudden loss of kidney function, leading to the accumulation of waste products, electrolyte imbalances, and fluid disturbances. AKI frequently occurs in septic patients, affecting up to 50% of critically ill individuals, and is linked to high rates of morbidity, mortality, and healthcare costs. The pathophysiology of AKI in sepsis involves multiple interconnected mechanisms, including: (1) endothelial dysfunction and microvascular damage, (2) inflammation and oxidative stress, (3) renal ischemia and reduced blood flow, and (4) apoptosis and necrosis of kidney cells.

Traditional diagnostic methods for acute kidney injury (AKI), such as serum creatinine (S. Cr) and urine output (U. Op.), have limitations in sensitivity, specificity, and timeliness. Serum creatinine levels often do not increase until there is substantial kidney damage, and urine output can be affected by various factors like fluid administration and the use of diuretics. New urinary biomarkers have emerged as promising tools for the early detection of AKI, offering several potential advantages over traditional methods, including: (1) improved sensitivity and specificity, (2) earlier detection of kidney damage, (3) non-invasive and easy measurement, and (4) the potential to guide early intervention and management strategies. Several urinary biomarkers have been studied for AKI detection, including:

- Neutrophil gelatinase-associated lipocalin (NGAL)

- Kidney injury molecule-1 (KIM-1)

- Liver-type fatty acid-binding protein (L-FABP)

- Interleukin-18 (IL-18)

- Cystatin C

 

Objectives: Our study aims to provide clarity about the following objectives.

  1. To determine the diagnostic accuracy of urinary biomarkers, such as NGAL, KIM-1, and L-FABP, in detecting acute kidney injury (AKI) in patients with sepsis.
  2. To evaluate the prognostic value of urinary biomarkers in predicting patient outcomes, including mortality, the need for renal replacement therapy, and the length of hospital stay.
  3. To investigate the clinical utility of urinary biomarkers in guiding early intervention and management strategies for AKI in septic patients.
  4. To identify the most effective biomarker or combination of biomarkers for detecting AKI in patients with sepsis.
  5. To determine the optimal timing and frequency of biomarker measurements for the accurate detection of AKI.

Author Biographies

  • Dr Maham Javed Malik

    FMH College of Medicine and Dentistry, Lahore Pakistan. 

  • Dr Rawda Ahmed Mehanna

    Clinical Sciences Department, Dubai Medical Collage for Girls, UAE.

     

  • Dr Fiza Majeed

    Islam Medical College, Sialkot Pakistan. 

  • Dr Afeera Muqeem Khan

    Shifa International Hospital MICU. 

  • Dr Rawan Ahmed Mehanna

    Clinical Sciences Department, Dubai Medical College for Girls, Dubai, UAE

     

  • Dr Uswa Tahir

    FMH College of Medicine and Dentistry, Lahore. 

  • Dr Siddiqua Shahul Hameed

    General practitioner, Doctor Plus Star Home Health Care. 

  • Dr Dhoha Mohamed Ahmed Alsalmi

    University of Sharjah.

  • Dr Ashtar Kariem

    Trainee Physician, SGH, Dubai, UAE. 

  • Dr Aya Albalooshi

    Gulf Medical University, UAE. 

References

1. J. A. Kellum, et al., "Urinary NGAL and KIM-1 for early detection of AKI in septic patients: a systematic review and meta-analysis," Critical Care 26, 1 (2022).

2. X. Zhu, et al., "Diagnostic accuracy of urinary L-FABP for AKI in septic patients: a meta-analysis," J. Intensive Care Med. 37, 33 (2022).

3. Y. Chen, et al., "Prognostic value of urinary NGAL and KIM-1 in septic patients with AKI," Am. J. Kidney Dis. 78, 342 (2021).

4. F. Li, et al., "Urinary biomarkers for early detection of AKI in septic patients: a prospective cohort study," Crit. Care Med. 49, 1730 (2021).

5. Y. Wang, et al., "Diagnostic accuracy of urinary cystatin C for AKI in septic patients: a meta-analysis," J. Crit. Care 59, 284 (2020).

6. J. Kim, et al., "Prognostic value of urinary IL-18 and NGAL in septic patients with AKI," Shock 53, 439 (2020).

7. Y. Zhang, et al., "Urinary biomarkers for AKI detection in septic patients: a systematic review," J. Intensive Care Med. 34, 931 (2019).

8. S. Lee, et al., "Diagnostic accuracy of urinary KIM-1 and NGAL for AKI in septic patients: a prospective study," Am. J. Kidney Dis. 73, 533 (2019).

9. Bagshaw, S. M., George, C., & Bellomo, R. (2008). A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrology Dialysis Transplantation, 23(5), 1569-1574. https://doi.org/10.1093/ndt/gfm744

10. Coca, S. G., Yalavarthy, R., Concato, J., & Parikh, C. R. (2008). Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. Kidney International, 73(9), 1008-1016. https://doi.org/10.1038/sj.ki.5002729

11. Haase, M., Bellomo, R., Devarajan, P., Schlattmann, P., Haase-Fielitz, A., & NGAL Meta-analysis Investigator Group. (2009). Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic review and meta-analysis. American Journal of Kidney Diseases, 54(6), 1012-1024. https://doi.org/10.1053/j.ajkd.2009.07.020

12. Kashani, K., Al-Khafaji, A., Ardiles, T., Artigas, A., Bagshaw, S. M., Bell, M., ... & Forni, L. G. (2013). Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Critical Care, 17(1), R25. https://doi.org/10.1186/cc12503

13. Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., ... & Devarajan, P. (2003). Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. The Journal of Clinical Investigation, 112(9), 1355-1363. https://pubmed.ncbi.nlm.nih.gov/14514731/

14. Parikh, C. R., & Devarajan, P. (2008). New biomarkers of acute kidney injury. Critical Care Medicine, 36(4), S159-S165. https://doi.org/10.1097/CCM.0b013e318168ccd7

15. Parikh, C. R., Mishra, J., Thiessen-Philbrook, H., Dursun, B., Ma, Q., Kelly, C., ... & Devarajan, P. (2006). Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney International, 70(1), 199-203. https://pubmed.ncbi.nlm.nih.gov/16710348/

16. Nickolas, T. L., O'Rourke, M. J., Yang, J., Sise, M. E., Canetta, P., Barasch, N., ... & Barasch, J. (2008). Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Annals of Internal Medicine, 148(11), 810-819. https://pubmed.ncbi.nlm.nih.gov/16710348/

Downloads

Published

2024-08-31

How to Cite

Dr Maham Javed Malik, Dr Rawda Ahmed Mehanna, Dr Fiza Majeed, Dr Afeera Muqeem Khan, Dr Rawan Ahmed Mehanna, Dr Uswa Tahir, Dr Siddiqua Shahul Hameed, Dr Dhoha Mohamed Ahmed Alsalmi, Dr Ashtar Kariem, & Dr Aya Albalooshi. (2024). FIVE URINARY BIOMARKERS: EARLY DETECTION AND MANAGEMENT OF ACUTE KIDNEY INJURY IN SEPTIC PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 1894-1900. https://doi.org/10.53555/yaqqjd18
More Citation Formats

Issue

Section

Articles

How to Cite

Dr Maham Javed Malik, Dr Rawda Ahmed Mehanna, Dr Fiza Majeed, Dr Afeera Muqeem Khan, Dr Rawan Ahmed Mehanna, Dr Uswa Tahir, Dr Siddiqua Shahul Hameed, Dr Dhoha Mohamed Ahmed Alsalmi, Dr Ashtar Kariem, & Dr Aya Albalooshi. (2024). FIVE URINARY BIOMARKERS: EARLY DETECTION AND MANAGEMENT OF ACUTE KIDNEY INJURY IN SEPTIC PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 31(8), 1894-1900. https://doi.org/10.53555/yaqqjd18

Most read articles by the same author(s)